At a glance
| Peptide length | 12 amino acids |
|---|---|
| Target pathway | TREM-1 inflammatory amplification |
| Main research setting | Septic shock |
| Phase 2b study | ASTONISH |
| Primary result | Prespecified efficacy endpoint not met |
Overview
Sepsis can involve harmful amplification of the host response to infection as well as inadequate immune function. Nangibotide was designed to modulate TREM-1-associated inflammatory amplification rather than act as an antibiotic. Clinical development has explored whether measuring soluble TREM-1 can identify patients most likely to respond. This is a precision-treatment hypothesis, not a validated general immune-balancing indication. The ASTONISH program provides substantial human research compared with many marketed research peptides, but its primary efficacy result was negative at the prespecified biomarker threshold. Later analyses with alternative thresholds should be presented as exploratory unless prospectively confirmed in a new controlled trial.
How it works
Nangibotide is derived from a TREM-like transcript-1-related sequence and is intended to interfere with ligand-dependent activation of TREM-1. TREM-1 amplifies inflammatory signaling in myeloid immune cells, so modulation may reduce excessive host-response injury. The proposed effect is not direct bacterial killing. Because immune responses vary over the course of sepsis, identifying the appropriate biology and timing is central to the therapeutic hypothesis.
What ASTONISH showed
ASTONISH included 355 participants in its main analysis and compared two nangibotide regimens with placebo. The prespecified improvement in organ-failure score was not demonstrated at the selected soluble TREM-1 cutoff or in the overall population. Adverse-event frequencies were broadly similar, but the study did not establish a survival benefit.
Supporting sources [1]
How should subgroup signals be read?
An analysis using higher soluble TREM-1 thresholds suggested a larger organ-failure-score response in some participants. This may guide a future study, but selecting a different cutoff after examining results can create optimistic estimates. Prospective validation with a defined assay, threshold, population, and endpoint is needed before routine selection of patients is justified.
The research setting limits generalization
The trials involved closely monitored patients receiving standard sepsis care. Similar event rates between trial arms do not establish the safety of outpatient immune modulation, chronic exposure, or use with a different infection. Sepsis itself produces many serious events, making both attribution and adequate comparator groups important.
Would it replace antibiotics or resuscitation?
No. The intervention was investigated as an addition to established septic-shock care, not as a substitute for infection treatment or organ support. Its proposed action concerns the host response. No FDA-approved general immunity, inflammation, or anti-aging indication can be inferred from this research program.
Reading this profile
Jurisdiction: United States and Europe: investigational TREM-1 modulation; no approved routine sepsis indication.. Molecular class: Synthetic 12-amino-acid TREM-1-modulating peptide.
This profile was written with AI-assisted research and checked against the linked sources. It has not been represented as a clinician’s review. Evidence summaries describe the cited studies and products; they do not establish that a separately purchased preparation is equivalent.
Sources & references
Follow the original material. Product labels define specific formulations and uses; trial registration describes a study and does not by itself establish benefit.
- ASTONISH randomized phase 2b trial ↗Original research · Checked 2026-10-27
- ASTONISH trial rationale and prospective protocol ↗Clinical trial source · Checked 2026-10-27
- ASTONISH registered study ↗Clinical trial source · Checked 2026-10-27